Floatz logo

Bempegaldesleukin

Locally Advanced or Metastatic Solid Tumours

Nykode Therapeutics ASAprotein_peptidePhase 1/2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Locally Advanced or Metastatic Solid Tumours cohort.

Asset / SponsorPhaseRating
gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV3-15*07 (86.9%)--(IGHD) -IGHJ1*01(90.9%), CDR-IMGT [8.10.9] (26-33.51-60.99-107))(1-118) -Homo sapiens IGHG1*01 (100%), G1m17,1 CH1K120, CH3 D12, L14 (CH1 K120 (215) (119-216),hinge 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfide with kappa light chain humanized (1'-220') [V-KAPPA (Homo sapiens IGKV2-24*01 (90.0%)-IGKJ2*01 (100%), CDR-IMGT [11.3.10] (27-37.55-57.94-103)) (1'-113') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (159), V101 (197) (114'-220')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa
AstraZeneca
Phase 2CCC
Durvalumab
AstraZeneca
Phase 2CCC
vb10.neo
Nykode Therapeutics ASA
Phase 1/2CCC
Valproic Acid
M.D. Anderson Cancer Center
Phase 1CC
89-zr-dfo-star polyethylene glycol
Robert Flavell, MD, PhD
Phase 1CC

View all 11 →

Same molecule, other indications

Bempegaldesleukin is also rated in:

melanomaDormant
CC
Indicative ·
46 / 100
View asset →
cutaneous melanomaDormant
CC
Indicative ·
46 / 100
View asset →
renal cell carcinomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →